8-K/A: Harrow to Acquire Melt Pharma, Expanding Ophthalmic Portfolio

Harrow, Inc. is set to acquire Melt Pharmaceuticals, Inc., a clinical-stage company focused on procedural sedation for cataract surgery, through a merger agreement that includes upfront cash and significant milestone payments.

Summary

• Harrow, Inc. (HROW) is acquiring Melt Pharmaceuticals, Inc. (Melt), a clinical-stage company developing MELT-300, a sublingual midazolam/ketamine tablet candidate for procedural sedation in cataract surgery.
• Harrow currently holds approximately 45% of Melt's outstanding capital stock and has been a significant investor and strategic partner.
• The merger consideration for Melt Common Stockholders includes an upfront cash payment of $0.50 per share, plus contingent milestone payments as detailed in the Milestone Payment Agreement.
• Melt Preferred Stock will automatically convert into Melt Common Stock immediately prior to the merger's effective time.
• Outstanding Melt Options, Warrants, and Restricted Stock Units (RSUs) will be cancelled and converted into the right to receive cash and contingent milestone payments based on a Per Share Fair Market Value (FMV) of $10.50.
• Harrow will use commercially reasonable efforts to pursue the development, regulatory approval, and commercialization of MELT-300, including obtaining a J-Code (or similar designation) from the Center for Medicare & Medicaid Services (CMS).
• Harrow will bear 100% of all transfer, documentary, sales, use, registration, stamp, and other similar taxes and fees arising from the agreement.
• Melt's defined contribution (401(k)) plan will be terminated no later than the day immediately preceding the Closing Date.
• During the interim period until closing, Harrow will advance funds to cover Melt's reasonable operating expenses, clinical study costs, and transaction expenses.

Sentiment

Score: 7

Explanation: The acquisition of Melt Pharmaceuticals by Harrow, Inc. is a strategically positive move, expanding Harrow's ophthalmic pipeline with a promising clinical-stage asset. The contingent payment structure aligns incentives and mitigates upfront risk. However, the significant portion of the consideration tied to future milestones introduces inherent regulatory and commercialization risks, which temper the immediate positive impact.

Positives

• Harrow is expanding its ophthalmic portfolio by acquiring a clinical-stage company with a promising candidate, MELT-300, which targets a specific need in procedural sedation for cataract surgery.
• The acquisition structure includes contingent milestone payments, aligning incentives and potentially reducing upfront risk for Harrow while offering significant upside for Melt's former shareholders upon successful development and commercialization.
• Harrow's commitment to use 'Commercially Reasonable Efforts' for MELT-300's development and commercialization indicates a strategic focus and dedication to realizing the asset's potential.
• Harrow will cover Melt's interim operating expenses, clinical study costs, and transaction expenses, providing financial stability for Melt until the closing of the merger.
• The boards of directors of both Melt and Harrow, through independent special committees, approved the merger after receiving fairness opinions, suggesting a well-vetted and equitable transaction.

Negatives

• Melt's former shareholders receive a relatively low upfront cash payment of $0.50 per share, with the majority of the potential value tied to future contingent milestones, which are subject to regulatory and commercial risks.
• The success of the contingent payments is dependent on achieving specific regulatory approvals (e.g., FDA, J-Code) and commercial performance (Annual Net Sales), which are inherently uncertain and could take many years to materialize.
• The termination of Melt's 401(k) plan prior to closing could create administrative burdens or potential disruption for Melt employees, despite other employee-related commitments from Harrow.

Risks

• Regulatory Risk: Achievement of significant milestone payments (e.g., $87.17 million for FDA approval, $47.94 million for J-Code) is contingent on obtaining regulatory approvals for MELT-300, which is a complex and uncertain process.
• Commercialization Risk: Commercial milestone payments (up to $99.98 million for $1 billion in annual net sales) depend on the successful market adoption and sales performance of Melt Products, particularly MELT-300, which is subject to market competition and acceptance.
• Integration Risk: Integrating Melt's clinical programs, intellectual property, and personnel into Harrow's existing operations could face challenges, potentially impacting efficiency and timelines.
• Employee Retention Risk: Changes in company ownership and the termination of Melt's 401(k) plan, despite other employee benefits, could affect employee morale and lead to key personnel departures.
• Intellectual Property Risk: While Melt represents it owns or has valid rights to use all necessary Intellectual Property Rights and that Melt Product does not infringe third-party IP, the pharmaceutical industry is prone to IP challenges and litigation.
• Litigation Risk: Although no legal proceedings are currently pending or threatened against Melt, the nature of the pharmaceutical business always carries a risk of future litigation related to product development, regulatory compliance, or intellectual property.

Future Outlook

Harrow intends to leverage its existing infrastructure and expertise to advance the development, regulatory approval, and commercialization of MELT-300, a sublingual midazolam/ketamine tablet candidate for procedural sedation in cataract surgery, with potential for broader label expansion. The company is committed to using commercially reasonable efforts to achieve key regulatory and commercial milestones for Melt Products, which will trigger significant contingent payments to Melt's former shareholders.

Management Comments

• The Melt Special Committee has determined that this Agreement and the Merger are advisable and in the best interests of Melt and its stockholders (other than Harrow) and recommended to the Melt Board to approve the Merger.
• The Harrow Special Committee has determined that this Agreement and the Merger are advisable and in the best interests of Harrow and its stockholders and recommended to the Harrow Board to approve the Merger.

Industry Context

This acquisition positions Harrow to strengthen its presence in the ophthalmic market by adding a clinical-stage asset, MELT-300, which targets procedural sedation for cataract surgery. The move aligns with a broader trend in the pharmaceutical industry where established companies acquire innovative smaller biotechs to expand their pipeline and market reach, particularly in specialized therapeutic areas. The contingent payment structure is a common strategy to mitigate risk in early-stage asset acquisitions and incentivize successful development and commercialization.

Comparison to Industry Standards

• The acquisition of a clinical-stage asset like MELT-300, with its potential for broader label expansion beyond cataract surgery, is consistent with strategic moves by other specialty pharmaceutical companies seeking to diversify their product portfolios and capture new market segments. For example, companies like Bausch + Lomb or Alcon frequently engage in similar acquisitions to bolster their ophthalmic offerings.
• The use of contingent value rights (CVRs) or milestone payments, as seen in this agreement, is a well-established mechanism in biotech M&A. This structure allows the acquirer (Harrow) to defer a significant portion of the purchase price until specific development, regulatory, or commercial milestones are achieved, thereby sharing risk with the selling shareholders (Melt). This approach has been utilized in numerous transactions, such as the acquisition of The Medicines Company by Novartis, where CVRs were tied to FDA approval of inclisiran.
• The upfront cash component of $0.50 per share, combined with potential milestone payments totaling up to $10.00 for FDA approval and $5.50 for J-Code, and further commercial milestones, suggests a valuation framework that is heavily weighted towards future success, typical for clinical-stage assets where significant de-risking is yet to occur. This contrasts with acquisitions of commercial-stage products which typically command higher upfront premiums.

Management Changes

Corporate Governance

Legal Proceedings

• No Legal Proceedings are pending or, to the Knowledge of Melt, threatened against Melt, and Melt is not subject to any outstanding judgment, decree, injunction, ruling or order.

Related Party Transactions

• Harrow, Inc. currently owns approximately 45% of the outstanding capital stock of Melt Pharmaceuticals, Inc., making this an acquisition of a significant minority-owned entity.

Stakeholder Impact

• Shareholders (Melt): Will receive an upfront cash payment and potential future contingent milestone payments, with value heavily dependent on MELT-300's successful development and commercialization.
• Shareholders (Harrow): The acquisition is expected to expand Harrow's product pipeline and market presence in ophthalmology, potentially increasing long-term shareholder value, but also introduces integration and commercialization risks.
• Employees (Melt): A 'Continuing Employee' is identified to receive comparable compensation and benefits for one year post-merger, and severance obligations will be honored for specific employees. Melt's 401(k) plan will be terminated, which may require employee action.
• Customers/Patients: Potential for new treatment options in procedural sedation for cataract surgery if MELT-300 is successfully developed and commercialized.
• Regulatory Authorities: The transaction involves ongoing regulatory compliance and submissions to the FDA and CMS for MELT-300.

Next Steps

• Melt to obtain Melt Disinterested Stockholders Approval and Melt Requisite Stockholder Approval.
• Melt to prepare and distribute an information statement to its stockholders describing the merger and their appraisal rights.
• Melt to terminate its 401(k) plan prior to the Effective Time.
• Harrow to deposit the Closing Cash Consideration with the Paying Agent at the Effective Time.
• Harrow to make contingent milestone payments upon the achievement of specified regulatory and commercial milestones for Melt Products.
• Harrow to use Commercially Reasonable Efforts to pursue the development, regulatory approval, and commercialization of MELT-300.
• Harrow to provide a written notice to the Stockholder Representative within five business days of achieving any Regulatory Milestone.
• Harrow to provide written reports summarizing Annual Net Sales of Melt Products within 45 days following the end of its fiscal year.

Key Dates

Recommendation

The acquisition of Melt Pharmaceuticals by Harrow, Inc. represents a strategic expansion into a specialized and potentially lucrative segment of the ophthalmic market. Harrow's existing 45% stake in Melt and its role as a strategic partner suggest a deep understanding of the asset and its potential. While a significant portion of the consideration is contingent on future milestones, this structure aligns incentives and mitigates upfront risk for Harrow. The commitment to 'Commercially Reasonable Efforts' for MELT-300's development and commercialization, coupled with Harrow's financial capacity to fund interim operations and transfer taxes, indicates a strong belief in the asset's value. Successful development and commercialization of MELT-300, particularly achieving FDA approval and a J-Code, could unlock substantial value, making this a compelling long-term 'buy' for investors seeking growth in the specialty pharmaceutical sector.

Keywords

Harrow Inc., Melt Pharmaceuticals, Merger, Acquisition, MELT-300, Ophthalmic, Procedural Sedation, Cataract Surgery, FDA Approval, J-Code, Milestone Payments, Pharmaceutical, Biotech, HROW